NASDAQ:XLRN - Acceleron Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$36.44 -0.13 (-0.36 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$36.44
Today's Range$36.29 - $37.31
52-Week Range$25.14 - $46.93
Volume139,578 shs
Average Volume309,672 shs
Market Capitalization$1.66 billion
P/E Ratio-13.60
Dividend YieldN/A
Beta1.45

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200

Debt

Debt-to-Equity RatioN/A
Current Ratio23.21
Quick Ratio23.21

Price-To-Earnings

Trailing P/E Ratio-13.60
Forward P/E Ratio-15.31
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million
Price / Sales123.76
Cash FlowN/A
Price / CashN/A
Book Value$7.73 per share
Price / Book4.71

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-839.98%
Return on Equity-34.52%
Return on Assets-32.40%

Miscellaneous

Employees139
Outstanding Shares45,780,000

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.06. The biopharmaceutical company earned $3.23 million during the quarter, compared to analysts' expectations of $3.77 million. Acceleron Pharma had a negative net margin of 839.98% and a negative return on equity of 34.52%. The company's revenue for the quarter was down 12.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.66) EPS. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

14 brokers have issued 12 month price objectives for Acceleron Pharma's shares. Their forecasts range from $33.00 to $69.00. On average, they anticipate Acceleron Pharma's stock price to reach $51.0769 in the next year. View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. Cann analysts commented, "While we have not modeled ACE-083 into our outlook for Acceleron by 2022, Fast Track designation has the potential to move the timeline for ACE-083 forward. Based on this and recently released positive results for ACE-083, we believe this program will continue to advance and will likely become a marketed drug." (5/1/2018)
  • 2. HC Wainwright analysts commented, "Preliminary ACE-083 Phase 2 Data Demonstrates Serious Gains in FSHD; Part 2 Current Underway Data demonstrates dose-dependent increases in total muscle volume. This morning, Acceleron Pharma announced preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) from the 150 and 200mg arms at the American Academy of Neurology (AAN) 70th Annual Meeting, which is being held in Los Angeles. ACE-083 demonstrated dose-dependent increases in total muscle volume in both the Tibalis Anterior (TA) and Biceps Brachii (BB) muscle cohorts, with a 15-20% increase observed at the higher dose level. In addition, a decrease in fat fraction was observed in both cohorts, however, it was more notable in the TA cohort. With regard to safety, ACE-083 was safe and generally well-tolerated in subjects for up to three months, which included five doses." (4/26/2018)
  • 3. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
  • Mr. Kevin F. McLaughlin, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 62)
  • Dr. Ravindra Kumar Ph.D., Chief Scientific Officer and Sr. VP (Age 58)
  • Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)

Has Acceleron Pharma been receiving favorable news coverage?

News articles about XLRN stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.81%), Farallon Capital Management LLC (3.06%), Westfield Capital Management Co. LP (3.00%), Eagle Asset Management Inc. (2.68%), Artal Group S.A. (1.86%) and Eventide Asset Management LLC (1.16%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Westfield Capital Management Co. LP, Eventide Asset Management LLC, American Century Companies Inc., Prudential Financial Inc., Artisan Partners Limited Partnership, Candriam Luxembourg S.C.A. and Citigroup Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.

Which major investors are buying Acceleron Pharma stock?

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, DekaBank Deutsche Girozentrale, Federated Investors Inc. PA, PNC Financial Services Group Inc., UBS Group AG, Artal Group S.A., Tiverton Asset Management LLC and Lord Abbett & CO. LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $36.44.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $1.66 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (XLRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acceleron Pharma (NASDAQ:XLRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $51.0769, suggesting that the stock has a possible upside of 40.17%. The high price target for XLRN is $69.00 and the low price target for XLRN is $33.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.632.592.61
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.0769$47.7333$45.3333$45.3750
Price Target Upside: 40.17% upside29.29% upside0.76% upside32.99% upside

Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History

Price Target History for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Credit Suisse GroupSet Price TargetBuy$55.00HighView Rating Details
5/9/2018HC WainwrightBoost Price TargetBuy$69.00LowView Rating Details
5/1/2018CannReiterated RatingHoldLowView Rating Details
3/1/2018CitigroupBoost Price TargetBuy ➝ Positive$44.00 ➝ $63.00HighView Rating Details
2/28/2018BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $54.00HighView Rating Details
2/28/2018Piper Jaffray CompaniesBoost Price TargetOverweight$53.00HighView Rating Details
2/26/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$33.00HighView Rating Details
1/8/2018OppenheimerReiterated RatingHoldMediumView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
9/12/2017UBSReiterated RatingBuy$36.00 ➝ $50.00HighView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 ➝ $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform ➝ Market PerformLowView Rating Details
5/17/2017Goldman Sachs GroupInitiated CoverageSell ➝ Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Acceleron Pharma (NASDAQ:XLRN) Earnings History and Estimates Chart

Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ:XLRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.62)($0.62)($0.62)
Q2 20183($0.70)($0.57)($0.63)
Q3 20183($0.69)($0.18)($0.47)
Q4 20183($0.83)($0.51)($0.69)
Q1 20191($0.76)($0.76)($0.76)
Q3 20191($0.72)($0.72)($0.72)

Acceleron Pharma (NASDAQ XLRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.65)N/AView Earnings Details
5/8/2018Q1 2018($0.64)($0.58)$3.77 million$3.23 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.60)($0.6180)$3.39 million$3.71 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.67)($0.65)$3.52 million$3.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)$8.00 million$4.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Acceleron Pharma (NASDAQ:XLRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acceleron Pharma (NASDAQ XLRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 87.44%
Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma (NASDAQ XLRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018John D QuiselSVPSell1,204$38.40$46,233.60View SEC Filing  
4/3/2018Kevin F MclaughlinCFOSell4,000$38.45$153,800.00View SEC Filing  
4/3/2018Matthew L ShermanEVPSell4,600$38.43$176,778.00View SEC Filing  
3/6/2018Richard F PopsDirectorSell37,500$41.42$1,553,250.0068,750View SEC Filing  
1/12/2018Christopher RovaldiSVPSell11,000$45.00$495,000.0035,701View SEC Filing  
1/4/2018Kevin F MclaughlinCFOSell19,000$42.89$814,910.0045,300View SEC Filing  
1/3/2018Christopher RovaldiSVPSell2,266$42.42$96,123.7252,977View SEC Filing  
1/3/2018Matthew L ShermanEVPSell4,633$42.71$197,875.4377,700View SEC Filing  
1/2/2018Kevin F MclaughlinCFOSell4,000$42.42$169,680.0045,300View SEC Filing  
12/15/2017Jean GeorgeDirectorSell105,122$35.73$3,756,009.061,250View SEC Filing  
9/25/2017Corp /De/ CelgeneMajor ShareholderBuy745,592$37.00$27,586,904.006,118,479View SEC Filing  
9/13/2017John D QuiselSVPSell5,113$38.42$196,441.4657,918View SEC Filing  
9/12/2017Christopher RovaldiSVPSell14,000$38.41$537,740.0028,232View SEC Filing  
9/12/2017Kevin F MclaughlinCFOSell16,000$38.41$614,560.0050,810View SEC Filing  
9/12/2017Matthew L ShermanEVPSell18,400$38.41$706,744.0079,750View SEC Filing  
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65108,392View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.0080,950View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00112,400View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.0096,264View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.0072,200View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.0098,100View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00130,977View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.004,000View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.881,624View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.1291,875View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.6077,004View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.3286,723View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00147,106View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26147,106View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20137,365View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84147,106View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.0082,900View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.0091,500View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08137,365View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00160,674View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.0095,524View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00131,098View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.005,372,887View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.0091,604View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00119,084View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.0080,000View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.0096,404View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.0056,685View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00119,656View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.0076,123View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.0021,584View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.0040,000View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00206,500View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.0027,656View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.004,572,887View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.004,867View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.0045,890View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.0027,656View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acceleron Pharma (NASDAQ XLRN) News Headlines

Source:
DateHeadline
Acceleron Pharma Inc (XLRN) Receives Consensus Rating of "Buy" from AnalystsAcceleron Pharma Inc (XLRN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 25 at 12:07 PM
Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of DirectorsPrevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors
www.bizjournals.com - May 24 at 5:42 PM
Wired News – Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial HypertensionWired News – Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial Hypertension
finance.yahoo.com - May 24 at 8:19 AM
$3.40 Million in Sales Expected for Acceleron Pharma Inc (XLRN) This Quarter$3.40 Million in Sales Expected for Acceleron Pharma Inc (XLRN) This Quarter
www.americanbankingnews.com - May 23 at 4:46 AM
Acceleron Pharma (XLRN) to Commence PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionAcceleron Pharma (XLRN) to Commence PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
www.streetinsider.com - May 22 at 5:09 PM
Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionAcceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
finance.yahoo.com - May 22 at 8:18 AM
-$0.64 EPS Expected for Acceleron Pharma (XLRN) This Quarter-$0.64 EPS Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - May 21 at 3:22 AM
Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology AssociationAcceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
finance.yahoo.com - May 17 at 6:42 PM
Acceleron Pharmas (XLRN) CEO Habib Dable on Q1 2018 Results - Earnings Call TranscriptAcceleron Pharma's (XLRN) CEO Habib Dable on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 8:26 AM
Oppenheimer Weighs in on Acceleron Pharmas Q2 2018 Earnings (XLRN)Oppenheimer Weighs in on Acceleron Pharma's Q2 2018 Earnings (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM
Piper Jaffray Comments on Acceleron Pharmas Q2 2018 Earnings (XLRN)Piper Jaffray Comments on Acceleron Pharma's Q2 2018 Earnings (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM
Leerink Swann Equities Analysts Reduce Earnings Estimates for Acceleron Pharma (XLRN)Leerink Swann Equities Analysts Reduce Earnings Estimates for Acceleron Pharma (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM
Credit Suisse Group Analysts Give Acceleron Pharma (XLRN) a $55.00 Price TargetCredit Suisse Group Analysts Give Acceleron Pharma (XLRN) a $55.00 Price Target
www.americanbankingnews.com - May 10 at 9:08 AM
HC Wainwright Raises Acceleron Pharma (XLRN) Price Target to $69.00HC Wainwright Raises Acceleron Pharma (XLRN) Price Target to $69.00
www.americanbankingnews.com - May 9 at 3:12 PM
Acceleron Pharma beats by $0.06, misses on revenueAcceleron Pharma beats by $0.06, misses on revenue
seekingalpha.com - May 8 at 5:40 PM
Acceleron: 1Q Earnings SnapshotAcceleron: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:40 PM
Acceleron Reports First Quarter 2018 Operating and Financial ResultsAcceleron Reports First Quarter 2018 Operating and Financial Results
finance.yahoo.com - May 8 at 5:40 PM
Acceleron Pharma (XLRN) Releases  Earnings Results, Beats Expectations By $0.06 EPSAcceleron Pharma (XLRN) Releases Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 8 at 5:24 PM
 Brokerages Expect Acceleron Pharma (XLRN) Will Announce Quarterly Sales of $4.35 Million Brokerages Expect Acceleron Pharma (XLRN) Will Announce Quarterly Sales of $4.35 Million
www.americanbankingnews.com - May 5 at 2:53 AM
Acceleron Pharma (XLRN) Upgraded by ValuEngine to BuyAcceleron Pharma (XLRN) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 5 at 12:29 AM
Traders Buy Large Volume of Put Options on Acceleron Pharma (XLRN)Traders Buy Large Volume of Put Options on Acceleron Pharma (XLRN)
www.americanbankingnews.com - May 4 at 8:46 AM
-$0.64 Earnings Per Share Expected for Acceleron Pharma (XLRN) This Quarter-$0.64 Earnings Per Share Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - May 3 at 9:31 PM
Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic Growth
finance.yahoo.com - May 3 at 8:16 AM
Acceleron Pharma Sees Unusually Large Options Volume (XLRN)Acceleron Pharma Sees Unusually Large Options Volume (XLRN)
www.americanbankingnews.com - May 3 at 8:15 AM
Acceleron Pharma (XLRN) Granted FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyAcceleron Pharma (XLRN) Granted FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
www.streetinsider.com - May 2 at 5:37 PM
Acceleron to Participate in Two Healthcare Investor Conferences in MayAcceleron to Participate in Two Healthcare Investor Conferences in May
finance.yahoo.com - May 2 at 8:20 AM
Accelerons ACE-083 Fast Trackd for type of muscular dystrophyAcceleron's ACE-083 Fast Track'd for type of muscular dystrophy
seekingalpha.com - May 1 at 5:18 PM
Acceleron Pharma (XLRN) Receives Hold Rating from CannAcceleron Pharma (XLRN) Receives Hold Rating from Cann
www.americanbankingnews.com - May 1 at 1:28 PM
Acceleron Pharma (XLRN) Receives Consensus Recommendation of "Hold" from AnalystsAcceleron Pharma (XLRN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 11:34 AM
Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
finance.yahoo.com - April 30 at 8:23 AM
Acceleron Pharma (XLRN) to Release Quarterly Earnings on MondayAcceleron Pharma (XLRN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:22 AM
Acceleron Pharma (XLRN) Given Buy Rating at HC WainwrightAcceleron Pharma (XLRN) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 26 at 4:22 PM
Acceleron Pharma (XLRN) Cut to "Hold" at ValuEngineAcceleron Pharma (XLRN) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - April 26 at 1:32 PM
Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual MeetingAcceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 26 at 8:16 AM
Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual MeetingAcceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
finance.yahoo.com - April 26 at 8:16 AM
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
finance.yahoo.com - April 22 at 8:17 AM
Acceleron Pharmas (XLRN) Hold Rating Reaffirmed at CannAcceleron Pharma's (XLRN) Hold Rating Reaffirmed at Cann
www.americanbankingnews.com - April 20 at 10:18 PM
Acceleron Pharma (XLRN) Receives "Buy" Rating from Credit Suisse GroupAcceleron Pharma (XLRN) Receives "Buy" Rating from Credit Suisse Group
www.americanbankingnews.com - April 19 at 11:52 PM
Acceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClubAcceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 19 at 9:23 AM
Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell"Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 18 at 10:23 AM
$4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter$4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - April 18 at 2:46 AM
Acceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per ShareAcceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 16 at 3:14 PM
Acceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment ResearchAcceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:26 PM
Q4 Biotech Catalyst Watchlist: Phase 3 Clinical TrialsQ4 Biotech Catalyst Watchlist: Phase 3 Clinical Trials
seekingalpha.com - April 10 at 8:25 AM
Acceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by BrokeragesAcceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 12:10 PM
Acceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 SharesAcceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 Shares
www.americanbankingnews.com - April 4 at 11:37 PM
Acceleron Pharma (XLRN) EVP Sells $176,778.00 in StockAcceleron Pharma (XLRN) EVP Sells $176,778.00 in Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Kevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) StockKevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Acceleron Pharma (XLRN) Lifted to Buy at ValuEngineAcceleron Pharma (XLRN) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Acceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 MillionAcceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 Million
www.americanbankingnews.com - April 1 at 2:36 AM

SEC Filings

Acceleron Pharma (NASDAQ:XLRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acceleron Pharma (NASDAQ:XLRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acceleron Pharma (NASDAQ XLRN) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.